Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

Zhao, Shimin, Lin, Yan, Xu, Wei, Jiang, Wenqing, Zha, Zhengyu, Wang, Pu, Yu, Wei, Li, Zhiqiang, Gong, Lingling, Peng, Yingjie, Ding, Jianping, Lei, Qunying, Guan, Kun-Liang, Xiong, Yue·2009·Science
DOI 10.1126/science.1170944

Cited by (999)

Items 701–800 of 999

  1. Aberrant Energy Metabolism in Tumors and Potential Therapeutic Targets
    Shuhao Fan, Jianhua Guo, Hui Nie, Huabao Xiong, Yong Xia · 2024 · Genes Chromosomes and Cancer
  2. Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers
    Kun Yao, Hua Liu, Jiajun Yin, Jianmin Yuan, Hong Tao · 2021 · Journal of Experimental & Clinical Cancer Research
  3. Correlation of immunohistochemical expression of HIF-1alpha and IDH1 with clinicopathological and therapeutic data of moroccan glioblastoma and survival analysis
    Fatima Sfifou, El Mehdi Hakkou, Arbi EL Bouaiti, Meriem Slaoui, Hassan H Errihani, Abderrahmane Al Bouzidi, Rédouane Abouqal, Abdessamad El Ouahabi, Nadia Cherradi · 2021 · Annals of Medicine and Surgery
  4. Correlation of Matrisome-Associatted Gene Expressions with LOX Family Members in Astrocytomas Stratified by IDH Mutation Status
    Talita de Sousa Laurentino, Roseli da Silva Soares, Suely Kazue Nagahashi Marie, Sueli Mieko Oba‐Shinjo · 2022 · International Journal of Molecular Sciences
  5. Hypoxia‐induced CXC chemokine ligand 14 expression drives protumorigenic effects through activation of insulin‐like growth factor‐1 receptor signaling in glioblastoma
    Sung‐Tai Wei, Jung‐Ying Chiang, Hwai‐Lee Wang, Fu‐Ju Lei, Yen‐Chih Huang, Chi‐Chung Wang, Der‐Yang Cho, Chia‐Hung Hsieh · 2022 · Cancer Science
  6. Sequence-structure functional implications and molecular simulation of high deleterious nonsynonymous substitutions in IDH1 revealed the mechanism of drug resistance in glioma
    Muhammad Suleman, Syeda Umme-I-Hani, Muhammad Salman, Mohammed Musfer Aljuaid, Abbas Khan, Arshad Iqbal, Zahid Hussain, Syed Shujait Ali, Liaqat Ali, Hassan Sher et al. · 2022 · Frontiers in Pharmacology
  7. Disruption of the HIF-1 pathway in individuals with Ollier disease and Maffucci syndrome
    Sarah R. Poll, Renan Paulo Martin, Elizabeth Wohler, Elizabeth S. Partan, Elizabeth Walek, Shaima Salman, Daniel Groepper, Lisa E. Kratz, Mirlene Cecília Soares Pinho Cernach, Reynaldo Jesús-García et al. · 2022 · PLoS Genetics
  8. Metabolic reprograming of cancer as a therapeutic target
    Tatsuhiko Furukawa, Sho Tabata, Kentaro Minami, Masatatsu Yamamoto, Kohichi Kawahara, Akihide Tanimoto · 2022 · Biochimica et Biophysica Acta (BBA) - General Subjects
  9. Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials
    Weronika Zając, Julia Dróżdż, Weronika Kisielewska, Weronika Karwowska, Monika Dudzisz‐Śledź, Agnieszka E. Zając, Aneta Maria Borkowska, Anna Szumera‐Ciećkiewicz, Bartłomiej Szostakowski, Piotr Lukasz Rutkowski et al. · 2023 · Cancers
  10. Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
    Giulia Trovarelli, Marta Sbaraglia, Andrea Angelini, Elena Bellan, Elisa Pala, Elisa Belluzzi, Assunta Pozzuoli, Chiara Borga, Angelo Paolo Dei Tos, Pietro Ruggieri · 2024 · Clinical Orthopaedics and Related Research
  11. Role of isocitrate dehydrogenase in glioma
    Brian Michael Alexander, Minesh P. Mehta · 2011 · Expert Review of Neurotherapeutics
  12. Novel ways to target brain tumour metabolism
    Daniel Stieber, Siti Aminah Abdul Rahim, Simone P. Niclou · 2011 · Expert Opinion on Therapeutic Targets
  13. Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors
    Xiaoqi Liu, Yuanyuan Hu, Anhui Gao, Meng Xu, Lixin Gao, Lei Xu, Yubo Zhou, Jianrong Gao, Qing Ye, Jia Xuan Li · 2018 · Bioorganic & Medicinal Chemistry
  14. IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5
    Bingdi Yan, Yanbing Hu, Tiangang Ma, Yanjun Wang · 2018 · Open Biology
  15. A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors
    Haihui Jiang, Xiaohui Ren, Wei Zhang, Jun Ma, Dali Sui, Zhongli Jiang, Xiangli Cui, Song Lin · 2012 · Journal of Neuro-Oncology
  16. Oncology's energetic pipeline
    Ken Garber · 2010 · Nature Biotechnology
  17. Deciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer
    Jie Hao, Ziyi Huang, Siyue Zhang, Kefan Song, Juncheng Wang, Chao Gao, Zhiqing Fang, Ning Zhang · 2024 · Pharmacological Research
  18. CDK5-triggered G6PD phosphorylation at threonine 91 facilitating redox homeostasis reveals a vulnerability in breast cancer
    Yuncheng Bei, Sijie Wang, Rui Wang, Owais Ahmad, Meng Jia, Pengju Yao, Jianguo Ji, Pingping Shen · 2024 · Acta Pharmaceutica Sinica B
  19. Therapeutic targeting of chromatin alterations in leukemia and solid tumors
    Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna M. Thomas, Michael W.M. Kühn, Michael Lübbert · 2025 · International Journal of Cancer
  20. IDH1 fine-tunes cap-dependent translation initiation
    Lichao Liu, J Yuyang Lu, Fajin Li, Xudong Xing, Tong Li, Xuerui Yang, Xiaohua Shen · 2019 · Journal of Molecular Cell Biology
  21. IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells
    Xiaoyu Hu, Luyuan Li, Josiane E. Eid, Chao Liu, Jinming Yu, Jinbo Yue, Jonathan C. Trent · 2022 · Disease Markers
  22. Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma
    Qing-Xin Wang, Peng-Yu Zhang, Qingqing Li, Zhen‐Jiang Tong, Shao‐Peng Yu, Yan‐Cheng Yu, Yan‐Cheng Yu, Ning Ding, Xue-Jiao Leng, Liang Chang et al. · 2023 · European Journal of Medicinal Chemistry
  23. Hypoxic regulation of extracellular vesicles: Implications for cancer therapy
    Seongkyeong Yoo, Sanga Choi, Iljin Kim, In‐San Kim · 2023 · Journal of Controlled Release
  24. PIWI-interacting RNAs (PiRNAs) as emerging biomarkers and therapeutic targets in biliary tract cancers: A comprehensive review
    Sahar Ahmadi Asouri, Esmat Aghadavod, Hamed Mirzaei, Alireza Abaspour, Mohammad Esmaeil Shahaboddin · 2024 · Heliyon
  25. The Biology and Management of Cartilaginous Tumors: A Role For Targeting Isocitrate Dehydrogenase
    Gabriel Tinoco, Breelyn Ann Wilky, Ana Cristina Paz-Mejia, Andrew Eric Rosenberg, Jonathan C. Trent · 2015 · American Society of Clinical Oncology Educational Book
  26. IDH1R132H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a
    Quanmin Nie, Yingying Lin, Xi Yang, Lin Shen, Liemei Guo, Shuanglin Que, Xiao-Xiong Li, Jianwei Ge, Guisong Wang, Wenhao Xiong et al. · 2015 · Molecular Medicine Reports
  27. Metabolic alteration in tumorigenesis
    Hui Yang, Yue Xiong, Kun‐Liang Guan · 2013 · Science China Life Sciences
  28. Enzymatic characterization of isocitrate dehydrogenase from an emerging zoonotic pathogen Streptococcus suis
    Peng Wang, Mingming Jin, Ruirui Su, Ping Song, Ming Wang, Guoping Zhu · 2011 · Biochimie
  29. Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution
    Haihui Jiang, Xiaohui Ren, Junmei Wang, Zhe Zhang, Wenqing Jia, Song Lin · 2013 · Journal of Neuro-Oncology
  30. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas
    Cody L. Nesvick, Chao Zhang, Nancy A. Edwards, Blake K. Montgomery, Michaela Lee, Chunzhang Yang, Herui Wang, Dongwang Zhu, John D. Heiss, Marsha J. Merrill et al. · 2016 · Journal of Neuro-Oncology
  31. Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma
    Victor M. Lu, Kerrie Leanne McDonald · 2018 · CNS Oncology
  32. The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner
    Peter Birner, Andrey Ivanov Tchorbanov, Sevdalin Natchev, Jochen Tuettenberg, Marin Guentchev · 2015 · Journal of Clinical Pathology
  33. Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas
    Ourania Romanidou, Vassiliki Kotoula, George Fountzilas · 2018 · Cancer Genomics & Proteomics
  34. Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention
    Shayan Cheraghlou, Young Hee Lim, Keith Adam Choate · 2019 · F1000Research
  35. Simplified perfusion fraction from diffusion-weighted imaging in preoperative prediction of IDH1 mutation in WHO grade II–III gliomas: comparison with dynamic contrast-enhanced and intravoxel incoherent motion MRI
    Xiaoqing Wang, Mengqiu Cao, Hongjin Chen, Jianwei Ge, Shiteng Suo, Yan Zhou · 2020 · Radiology and Oncology
  36. Heteroexpression and characterization of a monomeric isocitrate dehydrogenase from the multicellular prokaryote Streptomyces avermitilis MA-4680
    Ao Wang, Zhengyu Cao, Peng Wang, Aimin Liu, Wei Xing Pan, Jie Wang, Guoping Zhu · 2010 · Molecular Biology Reports
  37. Can metabolic plasticity be a cause for cancer? Warburg–Waddington legacy revisited
    Paike Jayadeva Bhat, Lalit A. Darunte, Venkatesh V. Kareenhalli, Jaswandi Ujwal Dandekar, Abhay Kumar · 2011 · Clinical Epigenetics
  38. Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3β
    Yuejun Fu, Yali Zheng, Kok‐Gan Chan, Aihua Liang, Fengyun Hu · 2014 · Molecular Biology Reports
  39. Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas
    Yuan Gu, Yu Wang, Yebin Wang, Jiaqian Luo, Xin Wang, Mingyue Ma, Wei Hua, Ying Liu, Fa‐Xing Yu · 2020 · Frontiers in Cell and Developmental Biology
  40. Roles of Chromatin Remodelling and Molecular Heterogeneity in Therapy Resistance in Glioblastoma
    Huey‐Miin Chen, Ana Nikolić, Divya Singhal, Marco Gallo · 2022 · Cancers
  41. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors
    Yosuke Kitagawa, Ami Kobayashi, Daniel P. Cahill, Hiroaki Wakimoto, Shota Tanaka · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  42. Glioblastomes : oncogenèse et bases biologiques
    Dominique F. Figarella-Branger, Carole Colin, Aurélie Tchoghandjian, Nathalie Baeza, Corinne Bouvier · 2010 · Neurochirurgie
  43. Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation
    Yukinari Kato, Mika Kato Kaneko · 2013 · Biochemical and Biophysical Research Communications
  44. 2‐Hydoxyglutarate: D/Riving Pathology in gLiomaS
    Daniel Richard Wahl, Sriram Venneti · 2015 · Brain Pathology
  45. A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas
    Olivera Casar‐Borota, Kristin Astrid Øystese, Magnus Sundström, Linea Cecilie Melchior, Vera M. POPOVIC · 2016 · Pituitary
  46. A high-throughput SAMDI-mass spectrometry assay for isocitrate dehydrogenase 1
    Sarah Elizabeth Anderson, Natalie S. Fahey, Jung Soo Park, Patrick T. O’Kane, Chad Alexander Mirkin, Milan Mrksich · 2020 · The Analyst
  47. The Inhibition of B7H3 by 2-HG Accumulation Is Associated With Downregulation of VEGFA in IDH Mutated Gliomas
    Mengli Zhang, Huaichao Zhang, Minjie Fu, Jingwen Zhang, Cheng Zhang, Yingying Lv, Fengfeng Fan, Jinsen Zhang, Hao Xu, Dan Ye et al. · 2021 · Frontiers in Cell and Developmental Biology
  48. Silybin suppresses ovarian cancer cell proliferation by inhibiting isocitrate dehydrogenase 1 activity
    Zibo Wei, Shuangyan Ye, Haipeng Feng, Chong Zeng, Xinhuai Dong, Xiaokang Zeng, Liming Zeng, Lin Xu, Qiuzhen Liu, Jie Yao · 2022 · Cancer Science
  49. Overexpression of isocitrate dehydrogenase-1R132H enhances the proliferation of A172 glioma cells via aerobic glycolysis
    Quanmin Nie, Guo Pin, Liemei Guo, JIN LAN, Yingying Lin, Fang Guo, Sunhai Zhou, Jianwei Ge, Qing Mao, XIAOXIONG LI et al. · 2015 · Molecular Medicine Reports
  50. Molecular Hallmarks of Gliomas
    Marta Pojo, Bruno Marques · 2011 · InTech eBooks
  51. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants
    Diego Avellaneda Matteo, Grace A. Wells, Lucas A. Luna, Adam J. Grunseth, Olga P. Zagnitko, David A. Scott, An D. Hoang, Amit Luthra, Manal A. Swairjo, Jamie M. Schiffer et al. · 2018 · Biochemical Journal
  52. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate
    Joseph P. Dexter, Patrick S. Ward, Tathagata Dasgupta, Aaron M. Hosios, Jeremy Gunawardena, Matthew G. Vander Heiden · 2018 · Journal of Biological Chemistry
  53. Wild-type IDH1 inhibits the tumor growth through degrading HIF-α in renal cell carcinoma
    Song Chen, Yejinpeng Wang, Yaoyi Xiong, Tianchen Peng, Mengxin Lü, Lian Zhang, Zhongqiang Guo · 2021 · International Journal of Biological Sciences
  54. Glioblastoma genetics: in rapid flux.
    Benjamin W. Purow, David Schiff · 2010 · PubMed
  55. Metabolism of glioma and IDH1/IDH2 mutations
    Marta Rossetto, Pietro Ciccarino, Blandine Boisselier, Marianne Labussière, Marc Sanson · 2011 · Revue Neurologique
  56. Pre-Clinical Analysis of Changes in Intra-cellular Biochemistry of Glioblastoma Multiforme (GBM) Cells Due to c-Myc Silencing
    Vishal Rajagopalan, Muthukumar Vaidyanathan, Vanisree Arambakkam Janardhanam, James E. Bradner · 2014 · Cellular and Molecular Neurobiology
  57. Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia
    Sam Humphries, Danielle R. Bond, Zacary P. Germon, Simon Keely, Anoop Kumar Enjeti, Matthew D. Dun, Heather J Lee · 2023 · Clinical Epigenetics
  58. Diverse roles of aldolase enzymes in cancer development, drug resistance and therapeutic approaches as moonlighting enzymes
    Fan Tang, Qingyang Cui · 2024 · Medical Oncology
  59. Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation
    Felix Sahm, David Capper, Jochen Meyer, Christian Johannes Hartmann, Esther Herpel, Mindaugas Andrulis, Gunhild Mechtersheimer, Iver Petersen, Werner Paulus, Andreas von Deimling · 2011 · Histopathology
  60. Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features
    Yong Zhu, Jun Chen, Weiwei Kong, Liang Mao, Wentao Kong, Qun Zhou, Zhengyang Zhou, Bin Zhu, Zhongqiu Wang, Jian He et al. · 2017 · European Radiology
  61. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications
    Sang Min Lee, Arielle Rose Urman, Pinkal M. Desai · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
  62. Opposed Interplay between IDH1 Mutations and the WNT/β-Catenin Pathway: Added Information for Glioma Classification
    Alexandre Vallée, Yves Lecarpentier, Jean-Noël Vallée · 2021 · Biomedicines
  63. Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches
    Markus J. Riemenschneider, Guido Reifenberger · 2009 · Current Opinion in Neurology
  64. Bioinformatics analysis reveals potential candidate drugs for different subtypes of glioma
    Xianzhen Chen, Weidong Zang, Fei Xue, Zhaoli Shen, Quanbin Zhang · 2012 · Neurological Sciences
  65. Methylglyoxal-induced modification of arginine residues decreases the activity of NADPH-generating enzymes
    Philip E. Morgan, Pamela J. Sheahan, David I. Pattison, Michael J. Davies · 2013 · Free Radical Biology and Medicine
  66. Hepatic expression of proteasome subunit alpha type‐6 is upregulated during viral hepatitis and putatively regulates the expression of ISG 15 ubiquitin‐like modifier, a proviral host gene in hepatitis C virus infection
    Ruth Broering, Martin Trippler, Melanie Werner, Catherine Isabell Real, Dominik Andre Megger, Thilo Bracht, Vincent Schweinsberg, Barbara Sitek, Martin Eisenacher, Helmut E. Meyer et al. · 2016 · Journal of Viral Hepatitis
  67. Patho-Epigenetics of Disease
    János Minárovits, Hans Helmut Niller · 2012 · Springer eBooks
  68. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome
    Thomas R. Reich, Olivier J. Switzeny, Mirjam Renovanz, Clemens Sommer, Bernd Kaina, Markus Christmann, Maja T. Tomicic · 2017 · Oncotarget
  69. Association between mutant IDHs and tumorigenesis in gliomas
    Shigeo Ohba, Yuichi Hirose · 2018 · Medical Molecular Morphology
  70. Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients
    Martin Voß, Kea Franz, Joachim Peter Steinbach, Emmanouil Fokas, Marie-Thérèse Forster, Katharina Filipski, Elke Hattingen, Marlies Wagner, Stella Breuer · 2019 · Journal of Neuro-Oncology
  71. Formation of new lymphatic vessels in glioma: An immunohistochemical analysis
    Fanwei Meng, Fusheng Liu, Wen‐Hui Liu, Li Li, Linlin Jie · 2020 · Neuropathology
  72. IDH1R132HMutation Increases U87 Glioma Cell Sensitivity to Radiation Therapy in Hypoxia
    Xiao-Wei Wang, Marianne Labussière, Samuel Valable, Elodie Anne Pérès, Jean‐Sébastien Guillamo, Myriam Bernaudin, Marc Sanson · 2014 · BioMed Research International
  73. The Distribution and Significance of IDH Mutations in Gliomas
    Marta Mellai, Valentina Caldera, Laura Annovazzi, Davide Schiffer · 2013 · InTech eBooks
  74. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy
    Caroline Bret, Elena Viziteu, Alboukadel Kassambara, Jérôme Moreaux · 2016 · Expert Review of Hematology
  75. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug
    Raffaele Addeo, M. Serena De Santi, Salvatore Del Prete, Michele Caraglia · 2009 · Cancer Chemotherapy and Pharmacology
  76. Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma—A Case Report and Systematic Review
    Alexander Yuile, Laveniya Satgunaseelan, Joe Wei, Marina Kastelan, Michael Back, Maggie C Lee, Heng Wei, Michael E. Buckland, Adrian V. Lee, Helen Wheeler · 2022 · Current Issues in Molecular Biology
  77. Differential metabolic alterations in IDH1 mutant vs. wildtype glioma cells promote epileptogenesis through distinctive mechanisms
    Darrian McAfee, Mitchell Moyer, Jaden Queen, Armin Mortazavi, Ujwal Boddeti, Muzna Bachani, Kareem A. Zaghloul, Alexander Ksendzovsky · 2023 · Frontiers in Cellular Neuroscience
  78. Low prevalence of IDH1 gene mutation in childhood AML in Italy
    Martina Pigazzi, Giulia Maria Ferrari, Riccardo Masetti, Brunangelo Falini, Francesco Martinolli, Giuseppe Basso, Andrea Biondi, Andrea Pession, Giovanni Cazzaniga · 2010 · Leukemia
  79. Cancer modelling in the NGS era – Part I: Emerging technology and initial modelling
    Ugo Rovigatti · 2015 · Critical Reviews in Oncology/Hematology
  80. Molecular prognostic factors in glioblastoma: state of the art and future challenges
    Ana Xavier‐Magalhães, Meera Nandhabalan, Chris Jones, Bruno Marques Costa · 2013 · CNS Oncology
  81. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis
    Moritz Perrech, Lena Dreher, Gabriele Röhn, Pantelis C. Stavrinou, Boris Krischek, Mohammad Reza Toliat, Roland Goldbrunner, Marco Timmer · 2019 · Technology in Cancer Research & Treatment
  82. Current development and future perspective of IDH1 inhibitors in cholangiocarcinoma
    Jorge Adeva · 2021 · Liver Cancer International
  83. Impact of Genetic Targets on Primary Brain Tumor Therapy: What’s Ready for Prime Time?
    Omar Akram Zalatimo, Christina Zoccoli, Anoop P. Patel, Claire L. Weston, Michael Glantz · 2012 · Advances in experimental medicine and biology
  84. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
    Jennie Webster Taylor, Andrew S Chi, Daniel P. Cahill · 2013 · PubMed
  85. Epigenetics and blood disorders
    Bastian Scholz, Rolf Marschalek · 2012 · British Journal of Haematology
  86. On the Utility of Short Echo Time (TE) Single Voxel 1H–MRS in Non–Invasive Detection of 2–Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel
    Hwon Heo, Sungjin Kim, Hyeong Hun Lee, Hye Rim Cho, Wen Jun Xu, Se‐Hoon Lee, Chul‐Kee Park, Sunghyouk Park, Seung Hong Choi, Hyeonjin Kim · 2016 · PLoS ONE
  87. Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy
    Luyuan Li, Josiane E. Eid, Ana Cristina Paz, Jonathan C. Trent · 2017 · BioDrugs
  88. Altered Metabolism of Leukemic Cells: New Therapeutic Opportunity
    Júlia Starková, Ivana Heřmanová, Kateřina Hložková, Alzbeta Hararova, Jan Trka · 2017 · International review of cytology
  89. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma
    Pingcuo Laba, Jianfeng Wang, Jin Zhang · 2018 · BMC Cancer
  90. Glyceraldehyde 3‐phosphate dehydrogenase modulates nonoxidative pentose phosphate pathway to provide anabolic precursors in hypoxic tumor cells
    Woo Suk Ahn, Wentao Dong, Zhe Zhang, Jason R. Cantor, David M. Sabatini, Othon Iliopoulos, Gregory N Stephanopoulos · 2018 · AIChE Journal
  91. Exploring the crosstalk of glycolysis and mitochondrial metabolism in psychiatric disorders and brain tumours
    Angeliki‐Maria Vlaikou, Markus Nußbaumer, Chrysoula Komini, Andromachi Lambrianidou, Constantinos Konidaris, Theoni T. Trangas, Michaela D. Filiou · 2020 · European Journal of Neuroscience
  92. The current state of molecular profiling in gastrointestinal malignancies
    Reetu Mukherji, Chao Yin, Rumaisa Hameed, Ali Jaber Alqahtani, Monika Kulasekaran, Aiwu Ruth He, Benjamin Adam Weinberg, John Lindsay Marshall, Marion L. Hartley, Marcus Smith Noel · 2022 · Biology Direct
  93. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility
    Hsin‐An Hou, Hwei‐Fang Tien · 2016 · Expert Review of Hematology
  94. Hypoxia, Gene Expression, and Metastasis
    Olga V. Razorenova, Amato J. Giaccia · 2010 · Springer eBooks
  95. Integration and Intersection of Cancer Metabolism with Epigenetic Pathways in Gliomas
    Siva Kumar Natarajan, Matthew J Pun, James Haggerty-Skeans, Sriram Venneti · 2025 · Annual Review of Pathology Mechanisms of Disease
  96. Metabolic Rewiring in Adult-Type Diffuse Gliomas
    Jong‐Whi Park · 2023 · International Journal of Molecular Sciences
  97. Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1
    Ryan Cordner, Michelle Jhun, Akanksha Panwar, HongQiang Wang, Nicole Gull, Ramachandran Murali, Joseph H. McAbee, Armen Mardiros, Akane Sanchez-Takei, Mia Mazer et al. · 2023 · Oncogene
  98. The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches
    Emily Gruber, Lev M. Kats · 2023 · Biochemical Society Transactions
  99. ALDH5A1/miR-210 axis plays a key role in reprogramming cellular metabolism and has a significant correlation with glioblastoma patient survival
    Indranil Mondal, Neelam Gupta, Vikas Sharma, Chitra Sarkar, Durga Prasad Mishra, Ritu Kulshreshtha · 2024 · Cancer Cell International
  100. Panoramic spatial enhanced resolution proteomics (PSERP) reveals tumor architecture and heterogeneity in gliomas
    Ziyan Xu, Yunzhi Wang, Tao Xie, Rongkui Luo, Hengli Ni, Xiang Hang, Shaoshuai Tang, Subei Tan, Rundong Fang, Peng Ran et al. · 2025 · Journal of Hematology & Oncology